Novel antiviral agents for respiratory viral infection in immunocompromised adults

Abstract

Respiratory viruses cause significant morbidity and mortality in immunocompromised populations such as stem cell transplant and solid organ transplant patients. Few viruses causing respiratory tract infection have an approved therapy, and many of the viruses have no therapeutic options at all. In this article, we describe novel agents under development for treatment options against several respiratory viruses. © 2013 Springer Science+Business Media New York.